This could potentially be achieved by using RNA interference-based
therapeutics that target expression of specific viral
RNAs. In a transient and transgenic mouse model of
HBV infection, it was recently shown that hepatocyte-targeted interference RNA specific for conserved HBV sequences resulted in repression of
HBsAg, HBeAg and viral DNA load